MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major demo targets were To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although one of several explor... https://salmeterol-xinafoate66543.blogdon.net/examine-this-report-on-antidepressant-agent-5-47036703